Login

CoViD-19: Inflammation and Molecular Imaging

20–23 May 2021
Remote
Europe/Rome timezone

Session

Diagnostics - Imaging Agents

21 May 2021, 15:00
Remote

Remote

Conveners

Diagnostics - Imaging Agents: Present Status

  • Marco Capogni (ENEA)
  • Arturo Chiti (Humanitas University – Milan – Italy)

Diagnostics - Imaging Agents: Molecular Imaging

  • José María Benlloch Baviera (I3M-CSIC)
  • Luca Filippi (Santa Maria Goretti Hospital, Latina )

Presentation materials

There are no materials yet.

  1. 61. Understanding the radiation risks associated with molecular imaging
    Michael K. O'Connor (Mayo Clinic, Section of Nuclear Medicine, Rochester)
    21/05/2021, 15:00
    Talk
  2. 62. Role of 2-[18F]FDG as a Radiopharmaceutical for PET/CT in patients with COVID-19
    Arturo Chiti (Humanitas University – Milan – Italy)
    21/05/2021, 15:20
    Talk
  3. 18. What molecular imaging of cancer patients can teach us about COVID-19
    Silvana Del Vecchio (Nuclear Medicine, Department of Advanced Biomedical Sciences, University Federico II)
    21/05/2021, 15:40
    Talk
  4. 20. 18F-FDG brain PET hypometabolism in post-SARS-CoV-2 infection: substrate for persistent/delayed disorders?
    Prof. E. Guedj (Nuclear Medicine, Univ. Marseille)
    21/05/2021, 16:15
    Talk
  5. 29. The role for dynamic imaging
    Irène Buvat (Curie Institute – Orsay)
    21/05/2021, 16:35
    Talk
  6. 89. The case for the Total Body PET imaging of CD8+ T Cells for researching COVID-19
    Terry Jones (University of California Davis)
    21/05/2021, 17:05
    Talk
  7. 66. Imaging Immune phenomena
    Martin Pomper (Johns Hopkins – Baltimore)
    21/05/2021, 17:25
    Talk
  8. 30. Potential Role of Conventional and Total Body PET Imaging in Assessing Systemic Complications of COVID Infection
    Abass Alavi (Penn Medicine, University of Pennsylvania)
    21/05/2021, 17:45
    Talk
Building timetable...